Advertisement
Screener

Merck & Co., Inc. (MRK) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Merck & Co., Inc. Comprehensive Income

Merck & Co., Inc. (MRK) reported Comprehensive Income of -$1.22 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-07

  • Merck & Co., Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$1.22B, a 130.65% decline year-over-year.
  • Merck & Co., Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$4.01B, a 179.32% decline year-over-year.
  • Merck & Co., Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $3.88B, a 6.98% decline year-over-year.
  • Merck & Co., Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $6.00B, a 90.78% increase year-over-year.
  • Merck & Co., Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $18.91B, a 9.11% increase from fiscal 2024.
  • Merck & Co., Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $17.33B.
  • Merck & Co., Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$28.00M, a 100.20% decline from fiscal 2022.
  • Merck & Co., Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $14.18B, a 4.22% decline from fiscal 2021.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month
2026-06-30-$1.22B
10-Q · filed 2026-08-07
-$5.23B
10-Q · filed 2026-08-07
-$1.35B
derived: sum of 3 quarters · filed 2026-08-07
$4.65B
derived: sum of 4 quarters · filed 2026-08-07
2026-03-31-$4.01B
10-Q · filed 2026-05-04
-$135.00M
derived: sum of 2 quarters · filed 2026-05-04
$5.87B
derived: sum of 3 quarters · filed 2026-05-04
$9.84B
derived: sum of 4 quarters · filed 2026-08-07
2025-12-31$3.88B
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$9.88B
derived: sum of 2 quarters · filed 2026-02-24
$13.85B
derived: sum of 3 quarters · filed 2026-08-07
$18.91B
10-K · filed 2026-02-24
2025-09-30$6.00B
10-Q · filed 2025-11-05
$9.97B
derived: sum of 2 quarters · filed 2026-08-07
$15.03B
10-Q · filed 2025-11-05
$19.20B
derived: sum of 4 quarters · filed 2026-08-07
2025-06-30$3.97B
10-Q · filed 2026-08-07
$9.03B
10-Q · filed 2026-08-07
$13.20B
derived: sum of 3 quarters · filed 2026-08-07
$16.35B
derived: sum of 4 quarters · filed 2026-08-07
2025-03-31$5.06B
10-Q · filed 2026-05-04
$9.23B
derived: sum of 2 quarters · filed 2026-05-04
$12.38B
derived: sum of 3 quarters · filed 2026-05-04
$17.74B
derived: sum of 4 quarters · filed 2026-05-04
2024-12-31$4.17B
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$7.32B
derived: sum of 2 quarters · filed 2026-02-24
$12.68B
derived: sum of 3 quarters · filed 2026-02-24
$17.33B
10-K · filed 2026-02-24
2024-09-30$3.15B
10-Q · filed 2025-11-05
$8.52B
derived: sum of 2 quarters · filed 2025-11-05
$13.16B
10-Q · filed 2025-11-05
$11.69B
derived: sum of 4 quarters · filed 2026-02-24
2024-06-30$5.37B
10-Q · filed 2025-08-05
$10.02B
10-Q · filed 2025-08-05
$8.55B
derived: sum of 3 quarters · filed 2026-02-24
$13.28B
derived: sum of 4 quarters · filed 2026-02-24
2024-03-31$4.65B
10-Q · filed 2025-05-02
$3.18B
derived: sum of 2 quarters · filed 2026-02-24
$7.91B
derived: sum of 3 quarters · filed 2026-02-24
$1.92B
derived: sum of 4 quarters · filed 2026-02-24
2023-12-31-$1.47B
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$3.26B
derived: sum of 2 quarters · filed 2026-02-24
-$2.73B
derived: sum of 3 quarters · filed 2026-02-24
-$28.00M
10-K · filed 2026-02-24
2023-09-30$4.73B
10-Q · filed 2024-11-06
-$1.26B
derived: sum of 2 quarters · filed 2024-11-06
$1.44B
10-Q · filed 2024-11-06
$4.43B
derived: sum of 4 quarters · filed 2025-02-25
2023-06-30-$5.99B
10-Q · filed 2024-08-05
-$3.29B
10-Q · filed 2024-08-05
-$294.00M
derived: sum of 3 quarters · filed 2025-02-25
$2.54B
derived: sum of 4 quarters · filed 2025-02-25
2023-03-31$2.71B
10-Q · filed 2024-05-03
$5.70B
derived: sum of 2 quarters · filed 2025-02-25
$8.53B
derived: sum of 3 quarters · filed 2025-02-25
$12.52B
derived: sum of 4 quarters · filed 2025-02-25
2022-12-31$2.99B
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
$5.82B
derived: sum of 2 quarters · filed 2025-02-25
$9.81B
derived: sum of 3 quarters · filed 2025-02-25
$14.18B
10-K · filed 2025-02-25
2022-09-30$2.83B
10-Q · filed 2023-11-03
$6.82B
derived: sum of 2 quarters · filed 2023-11-03
$11.19B
10-Q · filed 2023-11-03
$15.11B
derived: sum of 4 quarters · filed 2024-02-26
2022-06-30$3.99B
10-Q · filed 2023-08-07
$8.36B
10-Q · filed 2023-08-07
$12.28B
derived: sum of 3 quarters · filed 2024-02-26
$16.88B
derived: sum of 4 quarters · filed 2024-02-26
2022-03-31$4.37B
10-Q · filed 2023-05-05
$8.29B
derived: sum of 2 quarters · filed 2024-02-26
$12.89B
derived: sum of 3 quarters · filed 2024-02-26
$15.98B
derived: sum of 4 quarters · filed 2024-02-26
2021-12-31$3.92B
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26
$8.52B
derived: sum of 2 quarters · filed 2024-02-26
$11.61B
derived: sum of 3 quarters · filed 2024-02-26
$14.80B
10-K · filed 2024-02-26
2021-09-30$4.61B
10-Q · filed 2022-11-03
$7.70B
derived: sum of 2 quarters · filed 2022-11-03
$10.89B
10-Q · filed 2022-11-03
$8.54B
derived: sum of 4 quarters · filed 2023-02-24
2021-06-30$3.09B
10-Q · filed 2022-08-05
$6.28B
10-Q · filed 2022-08-05
$3.94B
derived: sum of 3 quarters · filed 2023-02-24
$6.89B
derived: sum of 4 quarters · filed 2023-02-24
2021-03-31$3.19B
10-Q · filed 2022-05-05
$846.00M
derived: sum of 2 quarters · filed 2023-02-24
$3.80B
derived: sum of 3 quarters · filed 2023-02-24
$6.80B
derived: sum of 4 quarters · filed 2023-02-24
2020-12-31-$2.35B
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24
$606.00M
derived: sum of 2 quarters · filed 2023-02-24
$3.61B
derived: sum of 3 quarters · filed 2023-02-24
$6.63B
10-K · filed 2023-02-24
2020-09-30$2.95B
10-Q · filed 2021-11-05
$5.95B
derived: sum of 2 quarters · filed 2021-11-05
$8.97B
10-Q · filed 2021-11-05
$10.53B
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30$3.00B
10-Q · filed 2021-08-09
$6.02B
10-Q · filed 2021-08-09
$7.57B
derived: sum of 3 quarters · filed 2022-02-25
$9.45B
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31$3.02B
10-Q · filed 2021-05-05
$4.57B
derived: sum of 2 quarters · filed 2022-02-25
$6.45B
derived: sum of 3 quarters · filed 2022-02-25
$9.10B
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31$1.55B
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
$3.43B
derived: sum of 2 quarters · filed 2022-02-25
$6.08B
derived: sum of 3 quarters · filed 2022-02-25
$9.20B
10-K · filed 2022-02-25
2019-09-30$1.87B
10-Q · filed 2020-11-05
$4.53B
derived: sum of 2 quarters · filed 2020-11-05
$7.64B
10-Q · filed 2020-11-05
$9.07B
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30$2.65B
10-Q · filed 2020-08-05
$5.77B
10-Q · filed 2020-08-05
$7.20B
derived: sum of 3 quarters · filed 2021-02-25
$9.12B
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$3.11B
10-Q · filed 2020-05-06
$4.55B
derived: sum of 2 quarters · filed 2021-02-25
$6.47B
derived: sum of 3 quarters · filed 2021-02-25
$8.11B
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$1.43B
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$3.35B
derived: sum of 2 quarters · filed 2021-02-25
$5.00B
derived: sum of 3 quarters · filed 2021-02-25
$5.86B
10-K · filed 2021-02-25
2018-09-30$1.92B
10-Q · filed 2019-11-05
$3.57B
derived: sum of 2 quarters · filed 2019-11-05
$4.43B
10-Q · filed 2019-11-05
$3.42B
derived: sum of 4 quarters · filed 2020-02-26
2018-06-30$1.65B
10-Q · filed 2019-08-06
$2.50B
10-Q · filed 2019-08-06
$1.49B
derived: sum of 3 quarters · filed 2020-02-26
$1.59B
derived: sum of 4 quarters · filed 2020-02-26
2018-03-31$860.00M
10-Q · filed 2019-05-08
-$151.00M
derived: sum of 2 quarters · filed 2020-02-26
-$58.00M
derived: sum of 3 quarters · filed 2020-02-26
$1.87B
derived: sum of 4 quarters · filed 2020-02-26
2017-12-31-$1.01B
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26
-$918.00M
derived: sum of 2 quarters · filed 2020-02-26
$1.01B
derived: sum of 3 quarters · filed 2020-02-26
$2.71B
10-K · filed 2020-02-26
2017-09-30$93.00M
10-Q · filed 2018-11-06
$2.02B
derived: sum of 2 quarters · filed 2018-11-06
$3.72B
10-Q · filed 2018-11-06
$2.15B
derived: sum of 4 quarters · filed 2019-02-27
2017-06-30$1.93B
10-Q · filed 2018-08-07
$3.63B
10-Q · filed 2018-08-07
$2.06B
derived: sum of 3 quarters · filed 2019-02-27
$4.08B
derived: sum of 4 quarters · filed 2019-02-27
2017-03-31$1.70B
10-Q · filed 2018-05-08
$128.00M
derived: sum of 2 quarters · filed 2019-02-27
$2.15B
derived: sum of 3 quarters · filed 2019-02-27
$3.46B
derived: sum of 4 quarters · filed 2019-02-27
2016-12-31-$1.57B
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$449.00M
derived: sum of 2 quarters · filed 2019-02-27
$1.76B
derived: sum of 3 quarters · filed 2019-02-27
$2.84B
10-K · filed 2019-02-27
2016-09-30$2.02B
10-Q · filed 2017-11-07
$3.33B
derived: sum of 2 quarters · filed 2017-11-07
$4.41B
10-Q · filed 2017-11-07
$5.81B
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30$1.31B
10-Q · filed 2017-08-08
$2.39B
10-Q · filed 2017-08-08
$3.79B
derived: sum of 3 quarters · filed 2018-02-27
$5.38B
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31$1.08B
10-Q · filed 2017-05-09
$2.48B
derived: sum of 2 quarters · filed 2018-02-27
$4.07B
derived: sum of 3 quarters · filed 2018-02-27
$4.59B
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31$1.40B
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$2.99B
derived: sum of 2 quarters · filed 2018-02-27
$3.51B
derived: sum of 3 quarters · filed 2018-02-27
$4.62B
10-K · filed 2018-02-27
2015-09-30$1.58B
10-Q · filed 2016-11-07
$2.11B
derived: sum of 2 quarters · filed 2016-11-07
$3.21B
10-Q · filed 2016-11-07
$9.21B
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30$522.00M
10-Q · filed 2016-08-08
$1.63B
10-Q · filed 2016-08-08
$7.62B
derived: sum of 3 quarters · filed 2017-02-28
$7.96B
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31$1.11B
10-Q · filed 2016-05-09
$7.10B
derived: sum of 2 quarters · filed 2017-02-28
$7.44B
derived: sum of 3 quarters · filed 2017-02-28
2014-12-31$5.99B
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
$6.33B
derived: sum of 2 quarters · filed 2017-02-28
$9.79B
10-K · filed 2017-02-28
2014-09-30$341.00M
10-Q · filed 2015-11-05
$3.80B
10-Q · filed 2015-11-05
2013-12-31$6.89B
10-K · filed 2016-02-26
2012-12-31$4.62B
10-K · filed 2015-02-27
2011-12-31$1.06B
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27
$2.86B
derived: sum of 2 quarters · filed 2014-02-27
$5.26B
derived: sum of 3 quarters · filed 2014-02-27
$6.36B
10-K · filed 2014-02-27
2011-09-30$1.80B
10-Q · filed 2011-11-08
$4.20B
derived: sum of 2 quarters · filed 2011-11-08
$5.30B
10-Q · filed 2011-11-08
2011-06-30$2.40B
10-Q · filed 2011-08-08
$3.50B
10-Q · filed 2011-08-08
2011-03-31$1.10B
10-Q · filed 2011-05-09
2010-09-30$1.50B
10-Q · filed 2011-11-08
$1.51B
10-Q · filed 2010-11-08
$1.17B
derived: sum of 2 quarters · filed 2011-11-08
$669.00M
10-Q · filed 2011-11-08
$669.20M
10-Q · filed 2010-11-08
2010-06-30-$335.00M
10-Q · filed 2011-08-08
-$841.00M
10-Q · filed 2011-08-08
2010-03-31-$506.00M
10-Q · filed 2011-05-09
2009-09-30$3.30B
10-Q · filed 2010-11-08
$6.28B
10-Q · filed 2010-11-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
AbbVie Inc. (ABBV)United States$468.180B70.37
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60